Pharmacological methods to transcriptionally modulate double-strand break DNA repair

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• DNA damage is a key mechanism in cancer therapy.
• Deficiencies in double-strand break (DSB) repair pathways, such as non-homologous end joining (NHEJ) and homology-directed repair (HDR), can sensitize cancer cells to treatments.
• Conventional small molecule inhibitors for DNA repair often face challenges with toxicity and bioavailability.

Purpose of the Study:

• To review pharmacological strategies that modulate DSB repair by decreasing DNA repair factor expression.
• To explore pathways influencing NHEJ and HDR activity, including growth/hormonal signaling and epigenetic modifiers.
• To discuss the impact of anti-angiogenic therapy on DSB repair.

Main Methods:

• Literature review of pharmacological manipulations affecting DNA repair.
• Analysis of pathways influencing NHEJ and HDR expression.
• Examination of preclinical and clinical data on modulating DSB repair in cancer therapy.

Main Results:

• Pharmacological reduction of DNA repair factor expression can enhance cancer cell sensitivity to DNA-damaging agents.
• Growth/hormonal signaling pathways and epigenetic modifiers are identified as modulators of NHEJ and HDR.
• Preclinical studies demonstrate increased sensitivity to ionizing radiation and PARP inhibitors through these manipulations.

Conclusions:

• Modulating DNA repair factor expression presents a promising therapeutic avenue in oncology.
• This approach may overcome limitations of traditional small molecule inhibitors.
• Further clinical investigation is warranted to optimize these strategies for cancer treatment.